$21,698.67 speaking Payment -- Bayer Healthcare to Dr. Donna Morgan
Radiologist Donna Morgan Earns Over $21,000 for Bayer Healthcare Speaking Engagements
This page provides a detailed analysis of a $21,698.67 speaking payment from Bayer Healthcare to Dr. Donna Morgan. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $21,698.67 |
| Payment Type | speaking |
| Payment Nature | Compensation for serving as faculty or as a speaker |
| Pharmaceutical Company | Bayer Healthcare |
| Physician | Dr. Donna Morgan |
| NPI Number | 1047500485 |
| Physician Specialty | Radiology |
| Location | Detroit, MI |
| Date of Payment | 2025-04-10 |
| Related Drug/Device | Farxiga |
| Conflict Assessment | Moderate -- Worth Noting |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Bayer Healthcare made a $21.7K speaking payment to Donna Morgan, a Radiology specialist in Detroit, MI. The payment was associated with Farxiga. Donna Morgan received $21,698.67 from Bayer Healthcare for speaking engagements related to Farxiga. The payment was for serving as faculty or a speaker, indicating an educational or promotional role. This payment represents a significant financial engagement between the physician and a pharmaceutical company.
Patient Guidance: What This Payment Means for You
If you are a patient, this information shows that your doctor may receive compensation for educating others about certain medications or devices. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
For a Radiology specialty, receiving compensation for speaking engagements is a common practice, though the amount here is on the higher side compared to typical speaker fees.
Regulatory Context: Sunshine Act Requirements
Payments for speaking engagements fall under the Sunshine Act's reporting requirements, intended to increase transparency in financial relationships between drug companies and healthcare providers.
Related Topics
This payment is related to the following healthcare transparency topics:
- speaker-fees
- educational-grants
- pharma-speaker-programs
- physician-compensation
- radiology-payments
- bayer-healthcare
- farxiga
Understanding speaking Payments
Speaking and education payments compensate physicians for presenting at conferences, continuing medical education (CME) events, and promotional speaking engagements. These payments often cover honoraria, preparation time, and travel expenses. Speaking fees are among the highest-value payment categories and have attracted significant attention from researchers studying potential conflicts of interest.
Frequently Asked Questions About This Payment
What was this $21.7K payment for?
This was a speaking payment of $21.7K from Bayer Healthcare to Donna Morgan, categorized as "Compensation for serving as faculty or as a speaker". It was associated with Farxiga. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Donna Morgan accept pharmaceutical money?
Yes, Donna Morgan received this $21.7K payment from Bayer Healthcare. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Donna Morgan's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this speaking payment?
A speaking payment of $21.7K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Radiology?
To compare this payment against Radiology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Radiology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Donna Morgan's relationship with Bayer Healthcare?
The payment amount is substantial, suggesting a considerable time commitment or perceived value for the speaking services. This $21.7K speaking payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Radiology?
The specific drug mentioned, Farxiga, indicates the focus of the speaking engagement.
What should patients do after learning about this payment?
If you are a patient, this information shows that your doctor may receive compensation for educating others about certain medications or devices.
What else should I know about this speaking payment?
The payment date is in the future (2025), which is unusual for reporting and may indicate a planned engagement.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.